Thrombosis among 1537 patients with JAK2V617F ‐mutated myeloproliferative neoplasms: Risk factors and development of a predictive model

We analyzed the clinical characteristics, laboratory characteristics, cytogenetics, thromboembolism status, disease progression, and overall survival of 1537 Chinese MPN patients with the JAK2V617F mutation. The multivariate analysis indicated that age ≥60 years old, HCT ≥48%, at least one cardiovascular risk factor, history of thrombosis, and JAK2V617F allele burden (V617F%) ≥50% are risk factors for thrombosis of JAK2V617F‐mutated MPN. Our study suggested that for elderly patients with JAK2V617F‐mutated MPN and a history of thrombosis, reducingV617F%, controlling HCT, and mitigating cardiovascular risk factors are necessary measures to prevent thrombosis. AbstractTo explore the risk factors of thrombosis in patients withJAK2V617F‐mutated myeloproliferative neoplasms (MPNs), a cohort of 1537 Chinese patients withJAK2V617F‐mutated MPN was retrospectively analyzed. The Kaplan‐Meier method and multivariate Cox analysis were used to study the risk factors of thrombosis in patients withJAK2V617F‐mutated MPN. Among the 1537 MPN patients, 931, 468, and 138 had polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), respectively. The median follow‐up time was 7 years (range 1‐47), and 12.8% of patients (197/1537) died during this period. A total of 16.8 % (259/1399) of PV and ET patients had secondary myelofibrosis, and 2.5% (38/1537) of patients developed acute myeloid leukemia (AML). Thrombotic events occurred in ...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research

Related Links:

Myeloproliferative disorders are a group of diseases morphologically linked by terminal myeloid cell expansion that frequently evolve from one clinical phenotype to another and eventually progress to acute myeloid leukemia. Diagnostic criteria for the Philadelphia chromosome –negative myeloproliferative neoplasms (MPNs) have been established by the World Health Organization and they are recognized as blood cancers. MPNs have a complex and incompletely understood pathogenesis that includes systemic inflammation, clonal hematopoiesis, and constitutive activation of the JAK-STAT pathway. Complications, such as thrombosi...
Source: Hematology/Oncology Clinics of North America - Category: Cancer & Oncology Authors: Source Type: research
Conclusions The discovery of JAK2V617F mutation in BCR-ABL1-negative MPNs by four different international cooperative groups in 2005 (2–5) led to significant insights on the pathogenesis of these disorders. In fact, this mutation results in a gain-of-function with activation of cytokine and growth factor receptors, and thus of the downstream JAK-STAT pathway (79, 95–98). The JAK2 point mutation in exon 12, present in a small percentage of patients with PV, is able to induce the MPN phenotype through the same pathogenic mechanism (6, 7). In 2006 the MPLW515L/K was reported in ET and PMF patients (44, 45) and d...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This article reviews existing data on cytoreduction, evaluating hydroxyurea, interferons, and ruxolitinib in ET and PV. This review evaluates whether evidence supports a more liberal strategy of cytoreduction for all patients with ET and PV. PMID: 30545998 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
NCI’s Center for Cancer Research (CCR) Grand Rounds Dr. Catriona Jamieson, M.D., Ph.D., is Associate Professor of Medicine, Chief of the Division of Regenerative Medicine, Co-Leader of the Hematologic Malignancies Program in the Division of Hematology-Oncology and Director of Stem Cell Research at the Moores UC San Diego Cancer Center. Dr. Jamieson specializes in myeloproliferative neoplasms (MPNs) and leukemia. Myeloproliferative neoplasms are a family of clonal bone marrow disorders in which the body overproduces blood cells. Myeloproliferative neoplasms can cause many forms of blood clotting including heart at...
Source: Videocast - All Events - Category: Journals (General) Tags: Upcoming Events Source Type: video
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | China Health | Heart | Laboratory Medicine | Leukemia | Myeloproliferative Disorders | Study | Thrombosis